No profile data available.
FibroBiologics, Inc. (FBLG) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Houston, United States, with about 15 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$18.65 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $7.86 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases.
FibroBiologics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$7.86 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Kezar Life Sciences, Inc. (KZR), Cue Biopharma, Inc. (CUE), Synlogic, Inc. (SYBX).